This post was originally published on this site
WASHINGTON (Reuters) – The U.S. Federal Trade Commission has reached a settlement agreement with Vyera Pharmaceuticals over allegations it sought to block generic versions of its drug Daraprim, they said in a court filing.
Litigation against Martin Shkreli will continue, the filing said.
